Physicians struggle to provide a quick and proper diagnosis of mTBI. Often the person looks, moves, and acts normally. While 90% of patients with minor head injury have no CT scan abnormalities, many go on to exhibit long-term neuropsychological dysfunction. Failure to make a correct diagnosis and timely selection of the appropriate treatment can have serious implications.
Early identification of patients at risk for long-term neuropsychological dysfunction could greatly improve opportunities for effective, targeted therapies. Yet, currently there is no simple point-of-care test available to physicians in the emergency room or hospital that can accomplish this.
Banyan Biomarkers, with support from the U.S. Department of Defense has successfully conducted several human feasibility studies and completed enrollment of 2000 patients for an international pivotal study. "A rapid and objective point-of-care test to evaluate traumatic brain injury will help millions of patients throughout the world," stated Jackson Streeter, MD, Chief Medical Officer of Banyan Biomarkers.
Another recent independent study published online by JAMA Neurology also favorably supports the ability of biomarkers to help evaluate mTBI.
This quick, accurate blood test may do more than help change the course of care. It may change the course of someone’s life.